[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,009,696
  • Shares Outstanding, K 1,241,222
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.31
  • Price/Sales 5.65
  • Price/Cash Flow 12.80
  • Price/Book 7.35

Options Overview Details

View History
  • Implied Volatility 28.16% (-5.14%)
  • Historical Volatility 21.66%
  • IV Percentile 29%
  • IV Rank 30.34%
  • IV High 43.61% on 05/22/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 6) 3.52 (2.68%)
  • Put/Call Vol Ratio 1.14
  • Today's Volume 26,526
  • Volume Avg (30-Day) 8,092
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 193,091
  • Open Int (30-Day) 163,285
  • Expected Range 127.81 to 134.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.12
  • Number of Estimates 8
  • High Estimate $2.49
  • Low Estimate $1.98
  • Prior Year $2.01
  • Growth Rate Est. (year over year) +5.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.64 +2.89%
on 04/27/26
142.97 -8.14%
on 04/09/26
-10.21 (-7.21%)
since 04/08/26
3-Month
127.64 +2.89%
on 04/27/26
157.29 -16.50%
on 02/11/26
-21.17 (-13.88%)
since 02/06/26
52-Week
96.18 +36.54%
on 05/12/25
157.29 -16.50%
on 02/11/26
+33.17 (+33.79%)
since 05/08/25

Most Recent Stories

More News
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

GILD : 131.33 (-2.04%)
Gilead Sciences Q1 Earnings Call Highlights

Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones...

GILD : 131.33 (-2.04%)
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue

Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue

GILD : 131.33 (-2.04%)
Gilead: Q1 Earnings Snapshot

Gilead: Q1 Earnings Snapshot

GILD : 131.33 (-2.04%)
Gilead Sciences Announces First Quarter Financial Results

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion

GILD : 131.33 (-2.04%)
Stocks Steady Before the Open as Investors Await U.S.-Iran Updates; Earnings and Economic Data on Tap

June S&P 500 E-Mini futures (ESM26) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.01% this morning as investors await the outcome of diplomatic efforts aimed at ending the Iran...

APP : 468.55 (-6.08%)
CPR.M.DX : 5.602 (+0.04%)
SHEL.LN : 3,097.042 (-1.27%)
SMCI : 35.37 (+5.21%)
MNST : 86.29 (+13.58%)
ABNB : 141.49 (+0.73%)
DASH : 163.93 (-4.33%)
DVA : 198.65 (+1.22%)
MCD : 275.75 (-2.80%)
ESM26 : 7,419.00s (+0.76%)
CRWV : 114.15 (-11.40%)
FTNT : 114.07 (+5.65%)
Gilead's HIV Franchise and Oncology Pipeline Could Tell Two Different Stories This Quarter

Barchart Research What to Expect from GILD Earnings GILD Generated May 6, 2026 Current Price $136.30 EPS Estimate $$1.89 Consensus Rating Moderate Buy Average Move 4.38% Gilead's HIV Franchise and Oncology...

GILD : 131.33 (-2.04%)
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow

Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow

GILD : 131.33 (-2.04%)
Stocks Set to Open Lower as Oil Prices Climb on Renewed Middle East Tensions, U.S. Jobs Data and Earnings Awaited

June S&P 500 E-Mini futures (ESM26) are down -0.12%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.10% this morning, pointing to a lower open on Wall Street as oil prices surged amid renewed...

APP : 468.55 (-6.08%)
CVS : 90.55 (+3.65%)
AAPL : 293.32 (+2.05%)
ANET : 141.77 (+0.01%)
SNDK : 1,562.34 (+16.60%)
TTD : 23.08 (-1.75%)
BRK.B : 475.94 (+0.18%)
CLX : 92.16 (+0.05%)
PFE : 25.68 (-1.42%)
ESM26 : 7,419.00s (+0.76%)
SHOP : 110.41 (-1.19%)
CRWV : 114.15 (-11.40%)
1 S&P 500 Stock to Own for Decades and 2 We Avoid

1 S&P 500 Stock to Own for Decades and 2 We Avoid

HLT : 316.78 (-1.10%)
PWR : 745.00 (-0.76%)
GILD : 131.33 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 137.79
2nd Resistance Point 135.56
1st Resistance Point 133.45
Last Price 131.33
1st Support Level 129.11
2nd Support Level 126.88
3rd Support Level 124.77

See More

52-Week High 157.29
Fibonacci 61.8% 133.95
Last Price 131.33
Fibonacci 50% 126.74
Fibonacci 38.2% 119.53
52-Week Low 96.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.